API | abrocitinib

abrocitinib (Cibinqo) Report issue

Small molecule Approved ^FDA Breakthrough Therapy ^FDA Priority Review ^FDA

Active Ingredient History

NOW

Abrocitinib, sold under the brand name Cibinqo, is a medication used for the treatment of atopic dermatitis (eczema). It is a Janus kinase inhibitor and it was developed by Pfizer. It is taken by mouth. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
- Jak1 protein (Rattus norvegicus) ^UniProt
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

Organizations (8)

Research & Development (8)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (10)

Approved Indications (1)

Dermatitis, Atopic (approved 2022)

Experimental Indications - Clinical Trial Phases 1-4 (10)

Dermatitis, Atopic (Phase 4)

Diabetes Mellitus, Type 1 (Phase 2)

Food Hypersensitivity (Phase 1)

Granuloma Annulare (Phase 2)

Healthy Volunteers (Phase 1)

Prurigo (Phase 2)

Pruritus (Phase 2)

Sarcoidosis (Phase 2)

Skin Diseases (Phase 2)

Stevens-Johnson Syndrome (Early Phase 1)

Overview

Highest Phase: Phase 4
# of Trials: 14
# of Trial Organizations: 8

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue